Article citationsMore>>
Scagliotti, G.V., Parikh, P., von Pawel, J., Biesma, B., Vansteenkiste, J., Manegold, C., Serwatowski, P., Gatzemeier, U., Digumarti, R., Zukin, M., Lee, J.S., Mellemgaard, A., Park, K., Patil, S., Rolski, J., Goksel, T., de Marinis, F., Simms, L., Sugarman, K.P. and Gandara, D. (2008) Phase III Study Comparing Cisplatin plus Gemcitabine with Cisplatin plus Pemetrexed in Chemotherapy-Naive Patients with Advanced-Stage Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 26, 3543-3551.
http://dx.doi.org/10.1200/JCO.2007.15.0375
has been cited by the following article:
-
TITLE:
Phase II Study of Carboplatin and Pemetrexed Followed by Gefitinib for Patients with Advanced Non-Small Cell Lung Cancer Harboring Sensitive EGFR Mutation
AUTHORS:
Saki Manabe, Fumihiro Oshita, Shuji Murakami, Tetsuro Kondo, Haruhiro Saito, Takeshi Kaneko, Kouzo Yamada
KEYWORDS:
Pemetrexed, Gefitinib, EGFR Mutation, Non-Small Cell Lung Cancer, Chemotherapy
JOURNAL NAME:
Journal of Cancer Therapy,
Vol.6 No.15,
December
14,
2015
ABSTRACT: We conducted a phase II study of combination chemotherapy with
carboplatin (Cb) and pemetrexed (Pem) followed by gefitinib (Gef) to determine
the effects and toxicities in patients with non-small cell lung cancer (NSCLC)
harboring sensitive EGFR mutation. Eligible patients received four courses of
Cb at a dose corresponding to a target area under the curve equal to 6 mg/mL·min and 500 mg/m2 Pem on day 1 every
three to four weeks followed by sequential Gef 250 mg once a day until tumor
progression. Sixteen of registered 28 patients responded to Cb and Pem
combination. Twenty-seven patients received sequential Gef and 8 non-responders
to Cb and Pem achieved PR. The overall response rate was 85.7%. Among the major
toxicities, grade 3 SGPT elevation, nausea and thrombosis were observed in 3, 3
and 1 patients, respectively, who received Cb and Pem, and grade 3 SGPT
elevation and dry skin were observed in 5 and 1 patients, respectively, who
received Gef. There was no febrile neutropenia and no treatment-related death.
The median progression-free survival time was 19.1 months. Among 21 patients
who were followed up for more than 2 years, 14 survived during that time. Cb
and Pem followed by Gef maintenance are recommended for further evaluation for
patients with metastatic NSCLC harboring sensitive EGFR mutation.
Related Articles:
-
Shuichi Tsukamoto, Koji Yamazaki, Ryo Mori, Masakazu Katsura, Hidenori Kouso, Daigo Kawano, Chie Ushijima, Sadanori Takeo
-
Takanori Ayabe, Masaki Tomita, Kunihide Nakamura
-
Takanori Ayabe, Masaki Tomita, Eiichi Chosa, Makoto Ikenoue, Yukie Shirasaki, Kunihide Nakamura
-
Dina A. Salem, Dina R. Ibrahim, Ahmed Ezzat, Azza M. Adel
-
Saki Manabe, Fumihiro Oshita, Shuji Murakami, Tetsuro Kondo, Haruhiro Saito, Takeshi Kaneko, Kouzo Yamada